283 related articles for article (PubMed ID: 21933667)
21. [Tartrate-resistant acid phosphatase--TRAP 5b--as a novel marker of bone resorption in patients with irreversible renal failure treated with dialysis].
Nowak Z; Konieczna M; Wańkowicz Z
Pol Merkur Lekarski; 2004 Aug; 17(98):138-41. PubMed ID: 15603322
[TBL] [Abstract][Full Text] [Related]
22. Effects of reduced dialysate calcium on calcium-phosphorus product and bone metabolism in hemodialysis patients.
Fiedler R; Deuber HJ; Langer T; Osten B; Mohan S; Jehle PM
Nephron Clin Pract; 2004; 96(1):c3-9. PubMed ID: 14752247
[TBL] [Abstract][Full Text] [Related]
23. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
24. Relationship between serum sclerostin, bone metabolism markers, and bone mineral density in maintenance hemodialysis patients.
Ishimura E; Okuno S; Ichii M; Norimine K; Yamakawa T; Shoji S; Nishizawa Y; Inaba M
J Clin Endocrinol Metab; 2014 Nov; 99(11):4315-20. PubMed ID: 25093620
[TBL] [Abstract][Full Text] [Related]
25. Bone turnover markers predict changes in bone mineral density after parathyroidectomy in patients with renal hyperparathyroidism.
Lu KC; Ma WY; Yu JC; Wu CC; Chu P
Clin Endocrinol (Oxf); 2012 May; 76(5):634-42. PubMed ID: 22007930
[TBL] [Abstract][Full Text] [Related]
26. Effects of calcitriol on type 5b tartrate-resistant acid phosphatase and interleukin-6 in secondary hyperparathyroidism.
Lu KC; Tseng CF; Wu CC; Yeung LK; Chen JS; Chao TY; Janckila AJ; Yam LT; Chu P
Blood Purif; 2006; 24(5-6):423-30. PubMed ID: 16888370
[TBL] [Abstract][Full Text] [Related]
27. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
28. Decreased blood lead levels after calcitriol treatment in hemodialysis patients with secondary hyperparathyroidism.
Lu KC; Wu CC; Ma WY; Chen CC; Wu HC; Chu P
Bone; 2011 Dec; 49(6):1306-10. PubMed ID: 21985997
[TBL] [Abstract][Full Text] [Related]
29. Effects of parathyroidectomy on blood bone markers and heart rate variability in patients with stage 5 chronic kidney disease.
Chen H; Cui Y; Xing C; Purrunsing Y; Zha X; Shen C; Zeng M; Yang G; Yu X; Zhang L; Jiang Y; Shen Z; Ma H; Yin C; Li Y; Wang N
Int Urol Nephrol; 2018 Dec; 50(12):2279-2288. PubMed ID: 30361964
[TBL] [Abstract][Full Text] [Related]
30. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
31. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
32. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers.
Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C
Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534
[TBL] [Abstract][Full Text] [Related]
33. Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients.
Kobayashi I; Shidara K; Okuno S; Yamada S; Imanishi Y; Mori K; Ishimura E; Shoji S; Yamakawa T; Inaba M
Life Sci; 2012 Jan; 90(5-6):212-8. PubMed ID: 22154904
[TBL] [Abstract][Full Text] [Related]
34. Using the ratio of serum osteoprotegerin ligand to osteoprotegerin to evaluate renal osteodystrophy in dialysis patients.
Grzegorzewska AE; Mlot M
Adv Perit Dial; 2005; 21():188-93. PubMed ID: 16686316
[TBL] [Abstract][Full Text] [Related]
35. Effects of treadmill exercise on bone mass, bone metabolism, and calciotropic hormones in young growing rats.
Iwamoto J; Shimamura C; Takeda T; Abe H; Ichimura S; Sato Y; Toyama Y
J Bone Miner Metab; 2004; 22(1):26-31. PubMed ID: 14691683
[TBL] [Abstract][Full Text] [Related]
36. Intravenous vitamin D therapy reduces PTH-(1-84)/large C fragments ratio in chronic hemodialysis patients.
Kihara T; Ichikawa H; Morimoto H; Yano A; Akagi S; Nakao K; Kohmoto H; Wada J; Kumagai I; Makino H
Nephron Clin Pract; 2004; 98(3):c93-100. PubMed ID: 15528944
[TBL] [Abstract][Full Text] [Related]
37. Low-calcium dialysate improves mineral metabolism in hemodialysis patients.
Fujimori A; Yorifuji M; Sakai M; Oyama M; Nakao N; Tokuyama M; Fukagawa M
Clin Nephrol; 2007 Jan; 67(1):20-4. PubMed ID: 17269595
[TBL] [Abstract][Full Text] [Related]
38. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
39. Increased levels of osteoprotegerin in hemodialysis patients.
Avbersek-Luznik I; Malesic I; Rus I; Marc J
Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
[TBL] [Abstract][Full Text] [Related]
40. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.
Naumnik B; Klejna K; Koc-Żórawska E; Myśliwiec M
Adv Med Sci; 2013; 58(2):382-7. PubMed ID: 23959668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]